What research is being done for pancreatic cancer treatments and screenings today? The next life-saving treatment for the disease may be on the horizon. These articles highlight the latest in pancreatic cancer research.
A clinical trial compares the effectiveness of two different types of immunotherapy with standard treatment after pancreatic cancer surgery.
A clinical trial tests the diabetes drug metformin and transplant rejection preventative rapamycin to act as maintenance chemotherapy for pancreatic cancer.
A clinical trial tests the combination of standard chemotherapy plus a common cold virus that has been modified to kill cancer cells.
Researchers are testing whether adding a monoclonal antibody to standard chemotherapy will make locally advanced pancreatic cancer qualify for surgery.
A clinical trial looks the effectiveness of NanoKnife surgery on pancreatic cancer tumors that cannot be removed by traditional surgery.
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
Targeted immunotherapy is the focus of a clinical trial that tests the drug ibrutinib, approved for leukemia treatment, against pancreatic cancer.
A clinical trial uses PEGPH20, a synthetic form of a human enzyme, to make treatment more effective in pancreatic cancer patients with high tumor pressure.
Trovagene is developing a liquid biopsy for pancreatic cancer patients, to allow doctors to test for cancer and track treatment response.
A clinical trial tests a drug that turns off chemical signals in the body that promote the growth of tumors and the spread of pancreatic cancer.
Drs. Allyson Ocean and David Tuveson explain why pancreatic cancer patients should participate in clinical trials at the time of diagnosis.
A clinical trial compares FOLFIRINOX plus stereotactic body radiation therapy (SBRT) with just FOLFIRINOX for pancreatic cancer that has spread locally.